Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

Exclusion Criteria

• •DSM-5 diagnosis of Substance Use Disorder other that cannabis or nicotine within the last year (recreational use is not exclusionary).
• •Currently undergoing active treatment for Cannabis Use Disorder other than low-level (once/week or less) psychosocial intervention.
• •Uncontrolled hypertension (resting systolic BP above 150 or diastolic above 95 mm Hg).
• •Cardiovascular disease, such as history of myocardial infarction and ischemia, heart failure, angina, severe arrhythmias, or EKG abnormalities (Wolf-Parkinson-White syndrome, Complete left bundle branch block, PR interval \<120 ms or \>200 ms, Prolonged QT interval (corrected) \>500 ms, Cardiac arrhythmias as defined by PACs \>3 per min or PVCs \>1 per min).
• •History of or current neurological illness, such as stroke, seizure disorders, neurodegenerative diseases, or organic brain syndrome.
• •Intellectual disability.
• •Pregnant or lactating.
• •Diabetes.
• •Significant kidney or liver impairment.
• •Any chronic or severe infectious disease, including HIV and hepatitis.
• •Cancer.
• •Use of any barbiturates, diazepam, diltiazem, verapamil, protease inhibitors, any anticonvulsant medications (including valproate/valproic acid, lamotrigine, carbamazepine, and clobazam), glipizide, glyburide, warfarin, and cyclophosphamide/ ifosfamide, due to potential interaction with CBD at the metabolic level.
• •Suicidal ideation currently or within last 6 months (score of \>/= 3 on the Columbia Suicide Severity Rating Scale).
• •Less than the lower limit of normal hemoglobin and hematocrit at screening.
• •Elevated transaminase levels \>3 times the ULN, accompanied by elevations in bilirubin \>2 times the ULN.